Advertisement

Journal of Neurology

, Volume 264, Issue 3, pp 591–594 | Cite as

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis

  • Felix C. NgEmail author
  • James Bice
  • Anne Rodda
  • Matthew Lee-Archer
  • Douglas E. Crompton
Letter to the Editors

Dear Sirs,

Intravenous tissue plasminogen activator (tPA) thrombolysis remains the only proven pharmacological treatment for acute ischemic stroke [1]. A common clinical scenario is where a patient with atrial fibrillation (AF) on therapeutic anticoagulation presents with an acute ischemic stroke but thrombolysis is absolutely contraindicated due to hemorrhagic risk.

Recently, dabigatran reversal with idarucizumab to facilitate thrombolysis in acute stroke patients on dabigatran has been proposed [ 2]. We present two patients, the first outside Europe, managed with this approach (Fig.  1).

Keywords

Dabigatran Acute Ischemic Stroke Perfusion Compute Tomography Hemispheric Stroke Hemispheric Infarct 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with ethical standards

Consent for case reports

Written consents were obtained by patient and families.

Conflicts of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Demaerschalk BM, Kleindorer DO, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy El Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE, American Heart Association Stroke Council and Council on Epidemiology and Prevention (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke 47:581–641CrossRefPubMedGoogle Scholar
  2. 2.
    Diener HC, Bernstein R, Butcher K, Campbell B, Cloud G, Davalos A, Davis S, Ferro JM, Grond M, Krieger D, Ntaios G, Slowik A, Touzé E (2016) Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. Int J Stroke 12:9–12CrossRefPubMedGoogle Scholar
  3. 3.
    Berrouschot J, Stoll A, Hogh T, Eschenfelder CC (2016) Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke 47:1936–1938CrossRefPubMedGoogle Scholar
  4. 4.
    Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Jam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520CrossRefPubMedGoogle Scholar
  5. 5.
    Schmohl M, Glund S, Harada A, Imazu S, De Smet M, Moschetti V, Ramael S, Ikushima I, Grünenfelder F, Reilly P, Stangeri J (2016) Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost. doi: 10.1160/TH16-05-0385 PubMedGoogle Scholar
  6. 6.
    Schafter N, Muller A, Wullner U (2016) Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab – a case report. J Stroke Cerebrovasc Dis 25:e126–e127CrossRefGoogle Scholar
  7. 7.
    Kafke W, Kraft P (2016) Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report. Case Rep Neurol 8:140–144CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Schulz JG, Kreps B (2016) Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke. J Neurol Sci 370:44CrossRefPubMedGoogle Scholar
  9. 9.
    Mutzenbach JS, Pikija S, Otto F, Halwachs U, Weymayr F, Sellner J (2016) Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab–a case report. Ann Clin Transl Neurol 3:889–892CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gawehn A, Ayari Y, Heuschkel C, Kaste M, Kermer P (2016) Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report. J Med Case Rep 10:269CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zhang J, Yang Y, Sun J, Xing Y (2014) Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2:81PubMedPubMedCentralGoogle Scholar
  12. 12.
    Ay H, Gungor L, Arsava EM, Rosand J, Vangel M, Benner T, Schwamm LH, Furie KL, Koroshetz WJ, Sorensen AG (2010) A score to predict early risk of recurrence after ischemic stroke. Neurology 72:128–135CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Felix C. Ng
    • 1
    Email author
  • James Bice
    • 1
  • Anne Rodda
    • 1
  • Matthew Lee-Archer
    • 1
  • Douglas E. Crompton
    • 1
  1. 1.Department of Neurology, Northern HealthEpping, MelbourneAustralia

Personalised recommendations